Results 321 to 330 of about 1,318,825 (382)
Clinical Need and Research Investment for Liver Cancer in Australia
Asia-Pacific Journal of Clinical Oncology, EarlyView.Liver cancer incidence and mortality rates have been rising in comparison to other common cancers, but research funding has not been commensurate. ABSTRACT Aim This study aims to better understand factors driving the rising burden and costs of primary liver cancer (PLC) in Australia, identify key epidemiological trends, and ascertain investment in PLC ...
Romario Nguyen +15 more
wiley +1 more source
Integrating Dialysis in Ex Situ Machine Perfusion: A Systematic Review and Meta‐Analysis of Outcomes
Artificial Organs, EarlyView.Dialysis‐enhanced EVMP effectively maintains biochemical homeostasis, potentially mitigating metabolic stress and extending perfusion duration. Functional outcomes varied depending on the organ type, with the most pronounced benefits observed in cardiac perfusion.
Yomna E. Dean +12 more
wiley +1 more source
Congenital aniridia: European COST action ANIRIDIA‐NET guidelines for diagnosis, management and care
Acta Ophthalmologica, EarlyView.Abstract Congenital aniridia is a rare ocular disorder affecting the majority of eye structures and can be associated with systemic manifestations. The main visible phenotypic characteristic is the partial or complete absence of the iris; however, foveal hypoplasia is a more frequent and reliable clinical sign. Other ocular comorbidities are associated
Davide Romano +26 more
wiley +1 more source
Alimentary Pharmacology &Therapeutics, EarlyView.This illustration summarises our primary findings highlighting the rising incidence of certain extra‐digestive cancers among persons with IBD over the 25‐year study duration (left), and the relative rates of extra‐digestive cancer incidence and mortality among persons with IBD in recent years (2010–2019) compared to their age‐ and sex‐matched controls (
Sanjay K. Murthy +13 more
wiley +1 more source
Alimentary Pharmacology &Therapeutics, EarlyView.Serum villin‐1 is a non‐invasive indicator of gut barrier damage and short‐term mortality in acutely decompensated cirrhosis. Incorporating villin‐1 assessment into risk stratification methods improves prognostic accuracy by capturing an essential, yet previously overlooked component of disease progression.
David Tornai +22 more
wiley +1 more source
Treatment options for immune‐related adverse events associated with immune checkpoint inhibitors
British Journal of Pharmacology, EarlyView.Abstract The immunotherapy revolution with the use of immune checkpoint inhibitors (ICIs) started with the clinical use of the first ICI, ipilimumab, in 2011. Since then, the field of ICI therapy has rapidly expanded — with the FDA approval of 10 different ICI drugs so far and their incorporation into the therapeutic regimens of a range of malignancies.
Yu Hua Chen +3 more
wiley +1 more source